XOFLUZA

Brand name authorized in: Austria Finland Hong Kong Ireland Lithuania New Zealand Poland Singapore United States

Active ingredients

The drug XOFLUZA contains one active pharmaceutical ingredient (API):

1 Baloxavir marboxil
UNII 505CXM6OHG - BALOXAVIR MARBOXIL

Baloxavir marboxil is a prodrug that is converted by hydrolysis to baloxavir, the active form that exerts anti-influenza activity. Baloxavir acts on the cap-dependent endonuclease (CEN), an influenza virus-specific enzyme in the polymerase acidic (PA) subunit of the viral RNA polymerase complex and thereby inhibits the transcription of influenza virus genomes resulting in inhibition of influenza virus replication.

Read about Baloxavir marboxil

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code
Group title
Classification
Baloxavir marboxil
J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AX Other antivirals
Discover more medicines within J05AX25

Medication package inserts

Below package inserts are available for further reading:

Title
Type
Country
Summary of Product Characteristics (SPC)
Structured Product Labeling (SPL/PLR)
US

Unique identifiers

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country
Identification scheme
Identifier(s)
FI
Lääkealan turvallisuus- ja kehittämiskeskus
Identifier(s): 091107, 505339
HK
Department of Health Drug Office
Identifier(s): 66116, 66117
LT
Valstybinė vaistų kontrolės tarnyba
Identifier(s): 1091736, 1091737
NZ
Medicines and Medical Devices Safety Authority
Identifier(s): 21174, 21175
PL
Rejestru Produktów Leczniczych
Identifier(s): 100446550, 100446566, 100468098
SG
Health Sciences Authority
Identifier(s): 15679P, 15680P
US
FDA, National Drug Code
Identifier(s): 50090-4102, 50090-4104, 50242-828, 50242-860